lobbying_activities: 1232028
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
This data as json
| id | filing_uuid | filing_type | registrant_name | registrant_id | client_name | filing_year | filing_period | issue_code | specific_issues | government_entities | income_amount | expense_amount | is_no_activity | is_termination | received_date |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1232028 | bd24e3ca-f214-478c-98cb-08fad39c688f | Q1 | MARSHFIELD CLINIC HEALTH SYSTEM | 57830 | MARSHFIELD CLINIC HEALTH SYSTEM | 2012 | first_quarter | PHA | Leukemia drug shortages are reaching crises dimensions, especially the recent shortage of cytarabine. In the United States, about 10,000 individuals are diagnosed with AML every year. Cytarabine is the backbone of AML therapy and is the basis for its cure. Without this drug patient outcomes are limited. We raised the concerns of shortages experienced by the Clinic to Senate and FDA | Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),SENATE | 130000 | 0 | 0 | 2012-04-18T12:40:39.350000-04:00 |